Cite
HARVARD Citation
Chi, K. et al. (n.d.). 792OA randomized phase II study of cabazitaxel (CAB) vs (ABI) abiraterone or (ENZ) enzalutamide in poor prognosis metastatic castration-resistant prostate cancer (mCRPC). Annals of oncology. p. . [Online].